Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL

Clinical trial NCT00330252 · COMPLETED

Trial details

NCT number: NCT00330252
Sponsor: Dana-Farber Cancer Institute
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukemia

Start date: 2006-05-01
Primary completion: 2013-01-01
Enrollment: 29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.